Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Zappasodi

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 6, 2002
Urinary proteins and renal dysfunction in patients with multiple myelomaA Corso, P Zappasodi, M Lazzarino
Haematologica|April 28, 2001
The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularityP Zappasodi, A Lorenzi, A Corso
Haematologica|August 16, 2000
Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case reportP Zappasodi, A Corso, C del Forno
Haematologica|August 29, 2001
Urinary proteins in multiple myeloma: strong correlation with the indices of tumor burdenP Zappasodi, C Pascutto, T Bosoni, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2017
Ponatinib-induced widespread ichthyosiform eruptionF Derlino, S Barruscotti, P Zappasodi, et al.
Annals of Hematology|July 11, 2002
Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injuryP Zappasodi, P Vitulo, E Volpini, et al.
European Journal of Haematology|October 26, 1999
A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpuraP Zappasodi, A Corso, C Castagnola, et al.
Haematologica|August 24, 1999
Transient response of myeloma clone to pamidronate therapyA Corso, C Astori, E Orlandi, et al.
Leukemia Research|November 13, 2007
Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomasM Varettoni, S Mangiacavalli, P Zappasodi, et al.
Haematologica|April 6, 1999
Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapyA Corso, A Nozza, M Lazzarino, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 6, 2002
Urinary proteins and renal dysfunction in patients with multiple myelomaA Corso, P Zappasodi, M Lazzarino
Haematologica|April 28, 2001
The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularityP Zappasodi, A Lorenzi, A Corso
Haematologica|August 16, 2000
Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case reportP Zappasodi, A Corso, C del Forno
Haematologica|August 29, 2001
Urinary proteins in multiple myeloma: strong correlation with the indices of tumor burdenP Zappasodi, C Pascutto, T Bosoni, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2017
Ponatinib-induced widespread ichthyosiform eruptionF Derlino, S Barruscotti, P Zappasodi, et al.
Annals of Hematology|July 11, 2002
Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injuryP Zappasodi, P Vitulo, E Volpini, et al.
European Journal of Haematology|October 26, 1999
A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpuraP Zappasodi, A Corso, C Castagnola, et al.
Haematologica|August 24, 1999
Transient response of myeloma clone to pamidronate therapyA Corso, C Astori, E Orlandi, et al.
Leukemia Research|November 13, 2007
Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomasM Varettoni, S Mangiacavalli, P Zappasodi, et al.
Haematologica|April 6, 1999
Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapyA Corso, A Nozza, M Lazzarino, et al.
Pageof 3